Merck Marches Keytruda Into Next Wave Of Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
ASCO is jumping off point as the company looks beyond melanoma and lung cancer to the next wave of potential cancer indications for its PD-1 inhibitor Keytruda, initiating pivotal trials in head & neck cancer and colorectal cancer.
You may also be interested in...
Genexine Gets Green Light For Stem Cell Cancer Trial
South Korean biotech firm Genexine’s R&D pipeline is progressing, with most of its therapies currently in Phase II clinical trials at home and abroad, and a new green light from domestic authorities to conduct a trial with a novel anticancer stem cell and gene therapy.
Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers
In Bristol’s CheckMate 067, PD-1 monotherapy performs as well as the PD-1/CTLA-4 combination in melanoma patients with higher expression of the PD-L1 biomarker, a finding that implies a personalized immunotherapy approach in the future.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.